New drug TPN-101 tested for rare brain disorder PSP
NCT ID NCT04993768
First seen May 01, 2026 · Last updated May 01, 2026
Summary
This study tested a drug called TPN-101 in 42 people with progressive supranuclear palsy (PSP), a rare brain disease that affects movement and thinking. The main goal was to see if the drug is safe and tolerable over 48 weeks. Researchers also looked at how the drug moves in the body and its effects on brain health markers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROGRESSIVE SUPRANUCLEAR PALSY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic Lou Ruvo Center for Brain Health
Las Vegas, Nevada, 89106, United States
-
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
Irving Center for Clinical and Translational Research
New York, New York, 10032, United States
-
Johns Hopkins University School of Medicine
Baltimore, Maryland, 21287, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Parkinson's Disease and Movement Disorders Center of Boca Raton
Boca Raton, Florida, 33486, United States
-
Quest Research Institute
Farmington Hills, Michigan, 48334, United States
-
Rocky Mountain Movement Disorders Center
Englewood, Colorado, 80113, United States
-
St. Joseph's Hospital and Medical Center, Barrow Neurological Institute
Phoenix, Arizona, 85013, United States
-
UC San Diego Altman Clinical And Translational Research Institute
La Jolla, California, 92037, United States
-
UCSF Neurosciences Clinical Research Unit (NCRU)
San Francisco, California, 94158, United States
-
UFHealth Fixel Institute for Neurological Diseases
Gainesville, Florida, 32608, United States
-
University of Texas Southwestern Medical Center
Dallas, Texas, 75390, United States
Conditions
Explore the condition pages connected to this study.